Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TolDec in MS and NMO
NCT02283671Phase 1Completed
- Sponsor
- Grifols
- Start
- Sep 2015
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple sclerosis (MS) and neuromyelitis optica (NMO), sponsored by Grifols. Primary endpoint: Number of patients with adverse events at 12 weeks. Started Sep 2015; status: completed.
02
Conditions
multiple sclerosis (MS)neuromyelitis optica (NMO)
Beyond the preview
Go deeper on NCT02283671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283671.